Patient One
Developing PO-003, a sustained-release cysteamine bitartrate formulation designed to reduce treatment burden while keeping cystinosis therapy accessible.
A proven medicine.
A better treatment experience.
Cysteamine can slow cystinosis progression, but immediate-release treatment requires strict, frequent dosing that is difficult to sustain in everyday life.
Patient One is developing PO-003, a sustained-release formulation intended for twice-daily dosing. Following proof-of-concept work and reformulation, the programme is preparing for further clinical testing.
science
structure
progression
access
Patient One
Cystinosis
The structure around the science.
Designed for development.
Designed for access.
Access should not become a question only after approval.
Patient One combines pharmaceutical development with a pricing and investment model intended to keep the treatment accessible once it reaches patients.